Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010–2020: A Cross-Sectional Study

[1]  E. Eworuke,et al.  A Boxed Warning for Montelukast: The FDA Perspective. , 2021, The journal of allergy and clinical immunology. In practice.

[2]  G. D. Dal Pan,et al.  An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System , 2020, Drug Safety.

[3]  B. Strom,et al.  Trends in Off-Label Drug Use in Ambulatory Settings: 2006–2015 , 2019, Pediatrics.

[4]  G. D. Dal Pan,et al.  The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System , 2019, Drug Safety.

[5]  G. D. Dal Pan,et al.  Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance , 2019, Drug Safety.

[6]  I. Edwards,et al.  Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre , 2019, Pharmacoepidemiology and drug safety.

[7]  R. Srivastava,et al.  Adverse Events in Hospitalized Pediatric Patients , 2018, Pediatrics.

[8]  G. D. Dal Pan,et al.  An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance , 2018, Drugs - Real World Outcomes.

[9]  S. L. Murphy,et al.  Annual Summary of Vital Statistics: 2013–2014 , 2017, Pediatrics.

[10]  J. Slattery,et al.  Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports , 2016, Pediatric Drugs.

[11]  G. Rosenthal,et al.  FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007–2013 , 2015, Pediatrics.

[12]  K. Verhamme,et al.  Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project , 2015, PloS one.

[13]  G. D. Dal Pan,et al.  Evaluation of FDA safety‐related drug label changes in 2010 , 2013, Pharmacoepidemiology and drug safety.

[14]  Su Golder,et al.  Adverse Drug Reactions in Children—A Systematic Review , 2012, PloS one.

[15]  Kristina Star,et al.  Suspected Adverse Drug Reactions Reported For Children Worldwide , 2011, Drug safety.

[16]  J. Cope,et al.  Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003–2007 , 2009, Pharmacoepidemiology and drug safety.

[17]  M. Lapeyre-Mestre,et al.  Adverse drug reactions and off-label drug use in paediatric outpatients. , 2002, British journal of clinical pharmacology.

[18]  P. Smith,et al.  Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration , 2019, JAMA pediatrics.

[19]  J. Hanley,et al.  Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. , 2016, JAMA internal medicine.